Squarepoint
IRD

Squarepoint’s Opus Genetics IRD Stock Holding History

Squarepoint’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-61,152
Closed -$184K – 4715
2023
Q4 		$184K Buy
61,152
+1,042
+2% +$3.08K ﹤0.01% 3628
2023
Q3 		$201K Buy
60,110
+25,278
+73% +$102K ﹤0.01% 3408
2023
Q2 		$151K Buy
+34,832
New +$165K ﹤0.01% 3285
2022
Q1 		– Sell
-10,655
Closed -$40K – 3645
2021
Q4 		$40K Buy
+10,655
New +$42.7K ﹤0.01% 3053
2021
Q3 		– Sell
-19,395
Closed -$102K – 3525
2021
Q2 		$102K Buy
19,395
+9,030
+87% +$44.8K ﹤0.01% 3010
2021
Q1 		$60K Sell
10,365
-9,207
-47% -$85.5K ﹤0.01% 2977
2020
Q4 		$127K Buy
+19,572
New +$135K ﹤0.01% 2665

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's IRD Position: Q1 2024 in Review

Squarepoint sold out of Opus Genetics (IRD) in Q1 2024, closing a stake of 61,152 shares — an estimated $184K sold.

Squarepoint first reported a position in IRD in Q4 2020 and held it in 7 quarters. The position peaked at $201K in Q3 2023. 49 funds tracked by Wall St. Rank hold IRD as of Q1 2024.

  • Squarepoint reported no remaining Opus Genetics position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 61,152 Opus Genetics shares in Q1 2024, an estimated $184K.
  • Squarepoint first reported a position in Opus Genetics in Q4 2020 and held it in 7 quarters.
  • Squarepoint's Opus Genetics position peaked at $201K in Q3 2023.
  • 49 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.